Arthur A. Levin - 18 Nov 2021 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Scientific Officer
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
18 Nov 2021
Net transactions value
-$666,646
Form type
4
Filing time
22 Nov 2021, 19:22:17 UTC
Previous filing
28 Jun 2021
Next filing
15 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $30,251 +24,396 +1834% $1.24* 25,726 18 Nov 2021 Direct F1
transaction RNA Common Stock Options Exercise $320 +604 +2.3% $0.5300* 26,330 18 Nov 2021 Direct F1
transaction RNA Common Stock Sale $697,218 -25,000 -95% $27.89 1,330 18 Nov 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -24,396 -13% $0.000000 166,770 18 Nov 2021 Common Stock 24,396 $1.24 Direct F1, F3
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -604 -1.4% $0.000000 41,743 18 Nov 2021 Common Stock 604 $0.5300 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.75 to $28.2150.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.
F4 This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.